PIDDosome-SCAP crosstalk controls high-fructose-diet-dependent transition from simple steatosis to steatohepatitis
- PMID: 36041455
- PMCID: PMC9547947
- DOI: 10.1016/j.cmet.2022.08.005
PIDDosome-SCAP crosstalk controls high-fructose-diet-dependent transition from simple steatosis to steatohepatitis
Abstract
Sterol deficiency triggers SCAP-mediated SREBP activation, whereas hypernutrition together with ER stress activates SREBP1/2 via caspase-2. Whether these pathways interact and how they are selectively activated by different dietary cues are unknown. Here, we reveal regulatory crosstalk between the two pathways that controls the transition from hepatosteatosis to steatohepatitis. Hepatic ER stress elicited by NASH-inducing diets activates IRE1 and induces expression of the PIDDosome subunits caspase-2, RAIDD, and PIDD1, along with INSIG2, an inhibitor of SCAP-dependent SREBP activation. PIDDosome assembly activates caspase-2 and sustains IRE1 activation. PIDDosome ablation or IRE1 inhibition blunt steatohepatitis and diminish INSIG2 expression. Conversely, while inhibiting simple steatosis, SCAP ablation amplifies IRE1 and PIDDosome activation and liver damage in NASH-diet-fed animals, effects linked to ER disruption and preventable by IRE1 inhibition. Thus, the PIDDosome and SCAP pathways antagonistically modulate nutrient-induced hepatic ER stress to control non-linear transition from simple steatosis to hepatitis, a key step in NASH pathogenesis.
Keywords: ER stress; IRE1; NAFLD; NASH; PIDDosome; SCAP; SREBP; caspase-2; steatohepatitis; steatosis.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests M.K. is the founder and scientific advisory board member of Elgia Therapeutics and receives research support from Merck, Jenssen, and Gossamer. J.Y.K. and M.K. are authors/inventors of patent titled Method for inhibition nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, and/or de novo lipogenesis (2017-152-2) (patent is pending approval).
Figures







Comment in
-
Cap CASP, not SCAP, to fight steatohepatitis.Cell Metab. 2022 Oct 4;34(10):1426-1428. doi: 10.1016/j.cmet.2022.09.014. Cell Metab. 2022. PMID: 36198289
References
-
- Abdelmalek MF, Lazo M, Horska A, Bonekamp S, Lipkin EW, Balasubramanyam A, Bantle JP, Johnson RJ, Diehl AM, Clark JM, et al. (2012). Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 56, 952–960. - PMC - PubMed
-
- Arguello G, Balboa E, Arrese M, and Zanlungo S (2015). Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 1852, 1765–1778. - PubMed
-
- Brown MS, and Goldstein JL (1997). The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 89, 331–340. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials